Euroscreen S.A.

Euroscreen's research activities began with the process of 'de-orphanizing' G protein-coupled receptors (GPCRs). This has been an important source of new targets for the development of our drug discovery programs and our patent portfolio.

We have most of the orphan human receptors cloned and expressed in cell lines suitable for functional testing. These cell lines are available for custom screening.

Euroscreen has one of the best, scientific track records of any biopharmaceutical company today for deorphanizing GPCRs.

Our expertise combines our in-house R&D, equipment and technologies to drive our research for these new targets. One of our competitive advantages comes from the wide collection of human and animal tissue extracts used for the screening and identification of natural ligands for these orphan GPCRs. These extracts are processed with different protocols to obtain either peptides, proteins, biogenic amines or lipid candidates as GPCR ligands. Moreover, most of the orphan human GPCRs have been cloned and expressed in recombinant cell lines adapted to functional screening. This expertise has been recognized by pharmaceutical companies that entered into collaborative programs with Euroscreen for selected orphan GPCRs, like Solvay Pharmaceuticals and Novartis.

Euroscreen has also established collaborations with academic groups and companies providing new ligand sources. Such interaction creates a synergy between Euroscreen discovery platforms and original ligand sources to characterize orphan receptors. In addition to others, Pharmadesign Inc. entered into such collaboration with Euroscreen in 2006.